Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Ophthalmology. 2020 Mar 29;127(9):1201–1210. doi: 10.1016/j.ophtha.2020.03.021

Figure 5.

Figure 5.

Mean change in optical coherence tomography central subfield thickness over time among follow-up study participants from a 2-year clinical trial on anti-vascular endothelial growth factor treatment for eyes with diabetic macular edema (Protocol T). Change in central subfield thickness was truncated to the mean ± 3 standard deviations of central subfield thickness change from baseline to 5 years (−154.5 ± 3 × 154.81). Eyes missing central subfield thickness at the 5-year visit were excluded.